MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.MAIA Biotechnology reported a $14.31M net loss for H1 2026, widening from $9.86M in 2025, with diluted EPS of $(0.27). The company remains pre-revenue. Clinically, it advanced Phase 2/3 trials for ateganosine in lung cancer, achieving a 90.5% disease control rate in interim results. Supported by a $33M equity offering, MAIA secured FDA clearance and partnerships with Regeneron, BeOne, and Roche, while planning new Phase 2 trials in hepatocellular, colorectal, and small cell lung cancers.
MAIA Biotechnology, Inc. reported a net loss of $(14.31M) for the six months ended June 30, 2026, compared with a $(9.86M) loss for the six months ended June 30, 2025. The company remains pre-revenue; diluted loss per share narrowed to $(0.27) for the six months ended June 30, 2026 from $(0.34) a year earlier.
Financial Highlights
- Revenue: No revenue reported for the periods presented (company continues to be pre-revenue).
- Net income: $(14.31M) net loss for six months ended Jun 30, 2026, versus $(9.86M) for six months ended Jun 30, 2025 (loss increased (45%) year over year).
- Diluted EPS: $(0.27) for six months ended Jun 30, 2026, versus $(0.34) for six months ended Jun 30, 2025.
Business Highlights
- Clinical progress: Initiated and expanded Phase 2 (THIO-101) and Phase 3 (THIO-104) trials of ateganosine in third-line non-small cell lung cancer with U.S. site activations.
- Regulatory & partnerships: FDA IND amendment cleared; supply agreements in place with Regeneron, BeOne and Roche to support checkpoint inhibitor combination studies.
- Clinical data momentum: Part C interim results showed a 90.5% disease control rate (19/21) and several earlier patients with more than two-year overall survival, supporting regulatory discussions.
- Funding & operations: A $33M equity offering in March 2026 funded the pivotal Phase 3 and expansion activities, enabling increased clinical enrollment and manufacturing updates.
- Pipeline expansion: Plans to start Phase 2 trials in hepatocellular carcinoma, colorectal cancer and small cell lung cancer, and to develop second-generation molecules with Phase 1 starts planned.
Original SEC Filing: MAIA Biotechnology, Inc. [ MAIA ] - 10-Q - Aug. 10, 2026